# Bowel Regimen Recommendations

**For Patients With a Functioning Gastrointestinal Tract**

---

## Pharmacologic Classes

- **Miralax** – Osmotic laxative  
- **Sennokot** – Stimulant laxative  
- **Milk of Magnesia** – Osmotic laxative  
- **Bisacodyl Suppository** – Stimulant laxative  
- **Lactulose** – Osmotic laxative  

---

## Initial Regimen (At Admission)

- **START:**
  * Sennokot 2 tablets BID  
  * AND Miralax 17 g daily  

---

## Escalation Pathway

### No Bowel Movement Within 48 Hours

#### Normal Renal Function
- **ADD** Milk of Magnesia 15 mL PO TID

#### Impaired Renal Function
- **ADD** Lactulose 20 g PO TID

---

### No Bowel Movement Within 72 Hours

#### Normal Renal Function
- **INCREASE** Milk of Magnesia to 30 mL PO TID  
- **ADD** Bisacodyl suppository 10 mg PR ×1

#### Impaired Renal Function
- **ADD** Bisacodyl suppository 10 mg PR ×1

---

### No Bowel Movement Within 96 Hours

- **ADD** SMOG enema 120 mL PR ×1  
- **CONSIDER** KUB

---

## Monitoring Considerations

### Physical Exam Red Flags (Consider KUB Imaging):

- Increased abdominal distention, discomfort, or firmness  
- Decreased or minimal flatus  
- Increased belching or hiccupping  
- Nausea or vomiting  

---

# Bowel Regimen Recommendations

**For Patients With a Non-Functioning Gastrointestinal Tract**

---

## If Ileus Is Suspected or Confirmed (Clinically or Radiographically)

- Place NG tube to low wall suction and monitor output  
- Make patient NPO  
- Initiate maintenance IV fluids  
- Monitor electrolytes as needed  
- Continue per rectal bowel regimen  
- Encourage ambulation, if appropriate  
- Repeat KUB as needed to monitor gas pattern  
- Discontinue or minimize offending medications:
  * Opioids  
  * Anticholinergics  
  * Dopamine agonists  
  * Anti-serotonergics  

---

## Pharmacologic Interventions

### If Ogilvie’s Syndrome Confirmed on Imaging

- **Consider neostigmine**  
  * Can only be administered on 10N  
  * **Use caution in patients with an anastomosis**

---

### For Postoperative Ileus or Opioid-Induced Constipation

#### Oral Naloxone

- **Initial dose:** 2 mg PO TID  
- **Max dose:** 4 mg PO TID  
- **Max duration:** 48 hours  
- **Monitor** for opioid reversal (especially in liver disease)

#### Methylnaltrexone

- **Dose:** 12 mg SQ ×1  
- **Repeat once** after 24 hours if no improvement  
- **Requirements:**
  * No obstruction confirmed on imaging  
  * Failed oral naloxone  
  * **Must discuss with attending before ordering**  
  * **Use caution in patients with an anastomosis**

---

# Management of Diarrhea

---

## Initial Steps

- **Stop** bowel regimen  
- **Monitor** electrolytes  

---

## If C. difficile Is Negative

- **Imodium** 4 mg q6h PRN  
- **Fiber supplementation:**
  * **Without feeding tube:**
    - Psyllium 2 caps daily (max 5 caps QID)
  * **With feeding tube:**
    - Nutrisource fiber 1 packet daily (max 6 packets/day; order under tube feeds)
  * Increase dose and frequency as needed

---

## References

1. Yang A, Lam T, Jierjian E, et al. An Evaluation of docusate monotherapy and the prevention of opioid-induced constipation after surgery. *J Pain Palliat Care Pharmacother.* 2022; 36(1):18–23.  
2. Gathers K, Fawad K, Petros K. Evaluation of methylnaltrexone bromide for the treatment of postoperative ileus. *Crit Care Med.* 2013; 41(12):929.  
3. Chamie K, Golla V, Lenis AT, et al. Peripherally Acting μ-Opioid Receptor Antagonists in the Management of Postoperative Ileus: a Clinical Review. *J Gastrointest Surg.* 2020. https://doi.org/10.1007/s11605-020-04671-x  
4. Valle RG, Godoy FL. Neostigmine for acute colonic pseudo-obstruction: a meta-analysis. *Ann Med Surg (Lond).* 2014; 3(3):60–64.  
5. Dudi-Venkata NN, Kroon HM, Bedrikovetski S, et al. Impact of STIMUlant and osmotic LAXatives (STIMULAX trial) on gastrointestinal recovery after colorectal surgery: randomized clinical trial. *Br J Surg.* 2021; 108(7):797–803.  
6. Beavers J, Orton L, Atchison L, et al. The Efficacy and Safety of Methylnaltrexone for the Treatment of Postoperative Ileus. *Am Surg.* 2022; 88(3):409–413.  
7. Gibson CM, Pass SE. Enteral naloxone for the treatment of opioid-induced constipation in the medical intensive care unit. *J Crit Care.* 2014; 29(5):803–807.  
8. Merchan C, Altshuler D, Papadopoulos J. Methylnaltrexone Versus Naloxone for Opioid-Induced Constipation in the Medical Intensive Care Unit. *Ann Pharmacother.* 51(3):203–208.  
9. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. *J Pain Symptom Manage.* 2002; 23(1):48–553.  

---

## Reviewed November 2024 By

- Caroline Banes, DNP, APRN, ACNP-BC  
- Jennifer Beavers, PharmD, BCPS  
- Jennifer Emerson, PharmD  
- Bethany Evans, MSN, ACNP-BC  
- Chelsea Tasaka, PharmD, BCCCP  
- Caroline Jackson, PharmD
